US 11744837
Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
granted A61KA61K31/567A61K31/585
Quick answer
US patent 11744837 (Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients) held by Corcept Therapeutics Incorporated expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 7
- CPC classes
- A61K, A61K31/567, A61K31/585, A61K45/06, A61P